India’s pharma giant Bharat Biotech has suffered a major setback in the United States. The U.S. Food and Drug Administration (FDA) has rejected the Covaxin vaccine for emergency use to fight against the corona pandemic. The Biden government has rejected proposals from Bharat Biotech regarding the Covaxin vaccine.
On the other hand, almost six months after the inclusion of the Covaxin vaccine in India, there has been a backlash in the US. It is reported that this is because Bharat Biotech company has not disclosed the third phase clinical trials data. Bharat Biotech said in a recent statement that approval of a biologic license application is also required for the Covaxin vaccine to be fully approved in the US.